|Articles|June 29, 2012

Flaws and All, This Is a Start

My thought is that it is good to move forward. No doubt there will be needed changes, but the status quo is broken.

Michael Glod, MD

My thought is that it is good to move forward. No doubt there will be needed changes, but the status quo is broken and as Roosevelt said during the depression, “Try something. Try anything. And if that doesn’t work, try something else.” Flaws and all, this is a start. Hopefully it won’t result in World War II between the political parties.

More on the Supreme Court Decision

Derek Raghavan

Bruce Minsky

Nora Janjan

Michael Glod

James B. Yu

Lawrence Wagman

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Flaws and All, This Is a Start

More on the Supreme Court Decision

Newsletter

Related Content

Disease Progression Noted After Epcoritamab/Glofitamab in R/R LBCL

Ociperlimab/Tislelizumab Plus cCRT Bolsters PFS/Responses in LS-SCLC

Zanubrutinib Exhibits Superior Long-Term Efficacy in First-Line CLL/SLL

What Are the Advantages of Immunotherapy-Based Backbones in Ph+ B-ALL?

Lower CRS Enables Outpatient Use of Anito-cel in R/R Multiple Myeloma

Latest CME

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Wisconsin

Breast Cancer Symposia in San Antonio

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Missouri

Burst CME™: How is the Newly Approved CAR T-Cell Therapy Impacting R/R B-Cell ALL Management?

Medical Crossfire® Navigating the Chronic Myeloid Leukemia Landscape: Treatment Strategies, Mechanisms, and Patient-Centered Care

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Kentucky

Tackling Oncologic Emergencies in Patients Treated with High-Dose Methotrexate

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Indiana

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

Community Oncology Connections ™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Missouri

Community Oncology Connections ™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | New Mexico

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | North Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | West Virginia

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Tennessee

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Washington

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | South Carolina

Community Oncology Connections ™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Texas

Cases and Conversations: Real-World Insights in Advancing Management of Myelofibrosis and Polycythemia Vera – How the Experts Apply the Latest Developments in Care

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Nevada

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arkansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kentucky

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

2nd Annual Hawaii Cancer Conference

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

11th Annual School of Gastrointestinal Oncology® (SOGO®)

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Cross-Disease Integration of Immunotherapy Innovations

Optimizing Treatment for Biliary Tract Cancers

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Radioligand Therapy 101: The Science Behind the Strategy